Close

Eyegate Pharma (EYEG) Responds to FDA Review, Addressing 3 of 4 Action Items in Second Amendment with Submission of Investigational Device Exemption

May 22, 2018 8:38 AM EDT Send to a Friend
EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) today announced that it has addressed three of the four outstanding items in a Second ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login